PML and breast adenocarcinoma: PML expression is absent in 49% of central nervous system (CNS) tumors (in 100% of medulloblastomas and over 90% of oligodendroglial tumors), 17% of colon adenocarcinomas, 21% of lung tumors, 27% of prostate adenocarcinomas, 31% of breast adenocarcinomas, 49% of germ cell tumors, and 68% of non-Hodgkin’s lymphomas (in 83% of diffuse large-cell lymphomas and 77% of follicular lymphomas) (29).